Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator

Peter A. Campochiaro, Gulnar Hafiz, Syed Mahmood Shah, Quan Dong Nguyen, Howard Ying, Diana V. Do, Edward Quinlan, Ingrid Zimmer-Galler, Julia A. Haller, Sharon D. Solomon, Jennifer U. Sung, Yasmin Hadi, Kashif A. Janjua, Nida Jawed, David F. Choy, Joseph R. Arron

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

Macular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). It is not clear how much of the edema is due to hydrodynamic changes from the obstruction and how much is due to chemical mediators. Patients with macular edema due to CRVO (n = 20) or BRVO (n = 20) were randomized to receive three monthly injections of 0.3 or 0.5 mg of ranibizumab. At the primary endpoint, month 3, the median improvement in letters read at 4 m was 17 in the 0.3-mg group and 14 in the 0.5-mg group for CRVO, and 10 and 18, respectively for the BRVO group. Optical coherence tomography (OCT) showed that compared to injections of 0.3 mg, injections of 0.5 mg of ranibizumab tended to cause more rapid reductions of central retinal thickening that lasted longer between injections, but in 3 months, excess central retinal thickening which is a quantitative assessment of the macular edema, was reduced by ∼90% in all four treatment groups. There was no correlation between the amount of improvement and duration of disease or patient age at baseline, but there was some correlation between the aqueous vascular endothelial growth factor (VEGF) level at baseline and amount of improvement. These data indicate that excess production of VEGF in the retinas of patients with CRVO or BRVO is a major contributor to macular edema and suggest that additional studies investigating the efficacy of intraocular injections of ranibizumab are needed.

Original languageEnglish (US)
Pages (from-to)791-799
Number of pages9
JournalMolecular Therapy
Volume16
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Retinal Vein Occlusion
Macular Edema
Vascular Endothelial Growth Factor A
Retinal Vein
Injections
Intraocular Injections
Ranibizumab
Optical Coherence Tomography
Hydrodynamics
Retina
Edema

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Campochiaro, P. A., Hafiz, G., Shah, S. M., Nguyen, Q. D., Ying, H., Do, D. V., ... Arron, J. R. (2008). Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator. Molecular Therapy, 16(4), 791-799. https://doi.org/10.1038/mt.2008.10

Ranibizumab for macular edema due to retinal vein occlusions : Implication of VEGF as a critical stimulator. / Campochiaro, Peter A.; Hafiz, Gulnar; Shah, Syed Mahmood; Nguyen, Quan Dong; Ying, Howard; Do, Diana V.; Quinlan, Edward; Zimmer-Galler, Ingrid; Haller, Julia A.; Solomon, Sharon D.; Sung, Jennifer U.; Hadi, Yasmin; Janjua, Kashif A.; Jawed, Nida; Choy, David F.; Arron, Joseph R.

In: Molecular Therapy, Vol. 16, No. 4, 04.2008, p. 791-799.

Research output: Contribution to journalArticle

Campochiaro, PA, Hafiz, G, Shah, SM, Nguyen, QD, Ying, H, Do, DV, Quinlan, E, Zimmer-Galler, I, Haller, JA, Solomon, SD, Sung, JU, Hadi, Y, Janjua, KA, Jawed, N, Choy, DF & Arron, JR 2008, 'Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator', Molecular Therapy, vol. 16, no. 4, pp. 791-799. https://doi.org/10.1038/mt.2008.10
Campochiaro, Peter A. ; Hafiz, Gulnar ; Shah, Syed Mahmood ; Nguyen, Quan Dong ; Ying, Howard ; Do, Diana V. ; Quinlan, Edward ; Zimmer-Galler, Ingrid ; Haller, Julia A. ; Solomon, Sharon D. ; Sung, Jennifer U. ; Hadi, Yasmin ; Janjua, Kashif A. ; Jawed, Nida ; Choy, David F. ; Arron, Joseph R. / Ranibizumab for macular edema due to retinal vein occlusions : Implication of VEGF as a critical stimulator. In: Molecular Therapy. 2008 ; Vol. 16, No. 4. pp. 791-799.
@article{07bcc296d6d64a1385513a8019b883bd,
title = "Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator",
abstract = "Macular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). It is not clear how much of the edema is due to hydrodynamic changes from the obstruction and how much is due to chemical mediators. Patients with macular edema due to CRVO (n = 20) or BRVO (n = 20) were randomized to receive three monthly injections of 0.3 or 0.5 mg of ranibizumab. At the primary endpoint, month 3, the median improvement in letters read at 4 m was 17 in the 0.3-mg group and 14 in the 0.5-mg group for CRVO, and 10 and 18, respectively for the BRVO group. Optical coherence tomography (OCT) showed that compared to injections of 0.3 mg, injections of 0.5 mg of ranibizumab tended to cause more rapid reductions of central retinal thickening that lasted longer between injections, but in 3 months, excess central retinal thickening which is a quantitative assessment of the macular edema, was reduced by ∼90{\%} in all four treatment groups. There was no correlation between the amount of improvement and duration of disease or patient age at baseline, but there was some correlation between the aqueous vascular endothelial growth factor (VEGF) level at baseline and amount of improvement. These data indicate that excess production of VEGF in the retinas of patients with CRVO or BRVO is a major contributor to macular edema and suggest that additional studies investigating the efficacy of intraocular injections of ranibizumab are needed.",
author = "Campochiaro, {Peter A.} and Gulnar Hafiz and Shah, {Syed Mahmood} and Nguyen, {Quan Dong} and Howard Ying and Do, {Diana V.} and Edward Quinlan and Ingrid Zimmer-Galler and Haller, {Julia A.} and Solomon, {Sharon D.} and Sung, {Jennifer U.} and Yasmin Hadi and Janjua, {Kashif A.} and Nida Jawed and Choy, {David F.} and Arron, {Joseph R.}",
year = "2008",
month = "4",
doi = "10.1038/mt.2008.10",
language = "English (US)",
volume = "16",
pages = "791--799",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Ranibizumab for macular edema due to retinal vein occlusions

T2 - Implication of VEGF as a critical stimulator

AU - Campochiaro, Peter A.

AU - Hafiz, Gulnar

AU - Shah, Syed Mahmood

AU - Nguyen, Quan Dong

AU - Ying, Howard

AU - Do, Diana V.

AU - Quinlan, Edward

AU - Zimmer-Galler, Ingrid

AU - Haller, Julia A.

AU - Solomon, Sharon D.

AU - Sung, Jennifer U.

AU - Hadi, Yasmin

AU - Janjua, Kashif A.

AU - Jawed, Nida

AU - Choy, David F.

AU - Arron, Joseph R.

PY - 2008/4

Y1 - 2008/4

N2 - Macular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). It is not clear how much of the edema is due to hydrodynamic changes from the obstruction and how much is due to chemical mediators. Patients with macular edema due to CRVO (n = 20) or BRVO (n = 20) were randomized to receive three monthly injections of 0.3 or 0.5 mg of ranibizumab. At the primary endpoint, month 3, the median improvement in letters read at 4 m was 17 in the 0.3-mg group and 14 in the 0.5-mg group for CRVO, and 10 and 18, respectively for the BRVO group. Optical coherence tomography (OCT) showed that compared to injections of 0.3 mg, injections of 0.5 mg of ranibizumab tended to cause more rapid reductions of central retinal thickening that lasted longer between injections, but in 3 months, excess central retinal thickening which is a quantitative assessment of the macular edema, was reduced by ∼90% in all four treatment groups. There was no correlation between the amount of improvement and duration of disease or patient age at baseline, but there was some correlation between the aqueous vascular endothelial growth factor (VEGF) level at baseline and amount of improvement. These data indicate that excess production of VEGF in the retinas of patients with CRVO or BRVO is a major contributor to macular edema and suggest that additional studies investigating the efficacy of intraocular injections of ranibizumab are needed.

AB - Macular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). It is not clear how much of the edema is due to hydrodynamic changes from the obstruction and how much is due to chemical mediators. Patients with macular edema due to CRVO (n = 20) or BRVO (n = 20) were randomized to receive three monthly injections of 0.3 or 0.5 mg of ranibizumab. At the primary endpoint, month 3, the median improvement in letters read at 4 m was 17 in the 0.3-mg group and 14 in the 0.5-mg group for CRVO, and 10 and 18, respectively for the BRVO group. Optical coherence tomography (OCT) showed that compared to injections of 0.3 mg, injections of 0.5 mg of ranibizumab tended to cause more rapid reductions of central retinal thickening that lasted longer between injections, but in 3 months, excess central retinal thickening which is a quantitative assessment of the macular edema, was reduced by ∼90% in all four treatment groups. There was no correlation between the amount of improvement and duration of disease or patient age at baseline, but there was some correlation between the aqueous vascular endothelial growth factor (VEGF) level at baseline and amount of improvement. These data indicate that excess production of VEGF in the retinas of patients with CRVO or BRVO is a major contributor to macular edema and suggest that additional studies investigating the efficacy of intraocular injections of ranibizumab are needed.

UR - http://www.scopus.com/inward/record.url?scp=41149085598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41149085598&partnerID=8YFLogxK

U2 - 10.1038/mt.2008.10

DO - 10.1038/mt.2008.10

M3 - Article

C2 - 18362932

AN - SCOPUS:41149085598

VL - 16

SP - 791

EP - 799

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 4

ER -